{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T19:10:09Z","timestamp":1778526609451,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"CIPRO (Centro Interprofessionale Pneumologico Ricerca ed Organizzazione), Genoa"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.pupt.2019.101836","type":"journal-article","created":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T19:14:59Z","timestamp":1567106099000},"page":"101836","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"special_numbering":"C","title":["One year of mepolizumab. Efficacy and safety in real-life in Italy"],"prefix":"10.1016","volume":"58","author":[{"given":"Diego","family":"Bagnasco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Caminati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Menzella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manlio","family":"Milanese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Rolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Bucca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Heffler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Paoletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Testino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiano","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Guida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianenrico","family":"Senna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Bonavia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Riccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio Walter","family":"Canonica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Passalacqua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2019.101836_bib1","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/1471-2458-12-204","article-title":"Global asthma prevalence in adults: findings from the cross-sectional world health survey","volume":"12","author":"To","year":"2012","journal-title":"BMC Public Health"},{"issue":"1","key":"10.1016\/j.pupt.2019.101836_bib2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12890-018-0689-2","article-title":"Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response","volume":"18","author":"Drick","year":"2018","journal-title":"BMC Pulm. Med."},{"issue":"2","key":"10.1016\/j.pupt.2019.101836_bib3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.pupt.2019.101836_bib4","article-title":"GINA 2017 guidelines","volume":"126","author":"Page","year":"2017","journal-title":"Glob. Initiat. Asthma"},{"key":"10.1016\/j.pupt.2019.101836_bib5","first-page":"45","article-title":"Nasal polyps in patients with asthma: prevalence, impact, and management challenges","volume":"9","author":"Langdon","year":"2016","journal-title":"J. Asthma Allergy"},{"issue":"1","key":"10.1016\/j.pupt.2019.101836_bib6","doi-asserted-by":"crossref","DOI":"10.1097\/ACI.0000000000000493","article-title":"Strategies to reduce corticosteroid-related adverse events in asthma","volume":"19","author":"Heffler","year":"2019","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.pupt.2019.101836_bib7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/MCP.0b013e328332ca2f","article-title":"Gastroesophageal reflux disease and asthma","volume":"16","author":"Parsons","year":"2010","journal-title":"Curr. Opin. Pulm. Med."},{"issue":"1","key":"10.1016\/j.pupt.2019.101836_bib8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/ACI.0000000000000492","article-title":"Bronchiectasis and asthma: a dangerous liaison?","volume":"19","author":"Crimi","year":"2019","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.pupt.2019.101836_bib9","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1586\/ers.11.34","article-title":"Asthma-related comorbidities","volume":"5","author":"Boulet","year":"2011","journal-title":"Expert Rev. Respir. Med."},{"issue":"1","key":"10.1016\/j.pupt.2019.101836_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1939-4551-7-27","article-title":"Vitamin D, allergies and asthma: focus on pediatric patients","volume":"7","author":"Della Giustina","year":"2014","journal-title":"World Allergy Organ J"},{"issue":"11","key":"10.1016\/j.pupt.2019.101836_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/nu9111234","article-title":"Asthmatic patients with vitamin D deficiency have decreased exacerbations after vitamin replacement","volume":"9","author":"Solidoro","year":"2017","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.pupt.2019.101836_bib12","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s11136-014-0801-x","article-title":"A qualitative study of the impact of severe asthma and its treatment showing that treatment burden is neglected in existing asthma assessment scales","volume":"24","author":"Hyland","year":"2015","journal-title":"Qual. Life Res."},{"issue":"1 Suppl","key":"10.1016\/j.pupt.2019.101836_bib13","doi-asserted-by":"crossref","first-page":"4S","DOI":"10.1378\/chest.130.1_suppl.4S","article-title":"The global burden of asthma","volume":"130","author":"Braman","year":"2006","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.pupt.2019.101836_bib14","article-title":"Type 2 immunity in asthma","volume":"11","author":"Caminati","year":"2018","journal-title":"World Allergy Organ J"},{"issue":"9842","key":"10.1016\/j.pupt.2019.101836_bib15","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.pupt.2019.101836_bib16","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.pupt.2019.101836_bib17","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.pupt.2019.101836_bib18","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200903-0392OC","article-title":"T-helper type 2-driven inflammation defines major subphenotypes of asthma","volume":"180","author":"Woodruff","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.pupt.2019.101836_bib19","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0014-2999(00)00690-7","article-title":"Enhancement of human eosinophil apoptosis by fluticasone propionate, budesonide, and beclomethasone","volume":"406","author":"Zhang","year":"2000","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.pupt.2019.101836_bib20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/1753465816673303","article-title":"Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience","volume":"11","author":"Varricchi","year":"2017","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.pupt.2019.101836_bib21","doi-asserted-by":"crossref","first-page":"5698212","DOI":"10.1155\/2018\/5698212","article-title":"Anti-IL-5 and IL-5Ra: efficacy and safety of new therapeutic strategies in severe uncontrolled asthma","volume":"2018","author":"Bagnasco","year":"2018","journal-title":"BioMed Res. Int."},{"issue":"1","key":"10.1016\/j.pupt.2019.101836_bib22","doi-asserted-by":"crossref","first-page":"40","DOI":"10.18176\/jiaci.0285","article-title":"Prospective open-label study of 48-week subcutaneous administration of mepolizumab in Japanese patients with severe eosinophilic asthma","volume":"29","author":"Kurosawa","year":"2019","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"issue":"1","key":"10.1016\/j.pupt.2019.101836_bib23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40413-018-0210-7","article-title":"The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials","volume":"11","author":"Bagnasco","year":"2018","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.pupt.2019.101836_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pupt.2018.09.006","article-title":"Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: results of a single-centre observational study","volume":"53","author":"Pelaia","year":"2018","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.pupt.2019.101836_bib25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.pupt.2018.12.003","article-title":"Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life","volume":"54","author":"Lombardi","year":"2019","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.pupt.2019.101836_bib26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1183\/09031936.05.00034505","article-title":"General considerations for lung function testing","volume":"26","author":"Miller","year":"2005","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.pupt.2019.101836_bib27","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.pupt.2019.101836_bib28","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.anai.2011.09.001","article-title":"Prospective evaluation of current asthma control using ACQ and ACT compared with GINA criteria","volume":"107","author":"Korn","year":"2011","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.pupt.2019.101836_bib29","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2147\/JAA.S150462","article-title":"Is it severe asthma or asthma with severe comorbidities?","volume":"10","author":"Brussino","year":"2017","journal-title":"J. Asthma Allergy"},{"issue":"10","key":"10.1016\/j.pupt.2019.101836_bib30","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jclinepi.2009.07.013","article-title":"Real-world effectiveness of new medicines should be evaluated by appropriately designed clinical trials. Journal of Clinical Epidemiology","volume":"63","author":"Freemantle","year":"2010","journal-title":"J. Clin. Epidemiol."},{"issue":"1","key":"10.1016\/j.pupt.2019.101836_bib31","doi-asserted-by":"crossref","first-page":"100007","DOI":"10.1016\/j.waojou.2018.12.001","article-title":"Shadow cost of oral corticosteroids-related adverse events: a pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry","volume":"12","author":"Canonica","year":"2019","journal-title":"World Allergy Organ J"},{"issue":"4","key":"10.1016\/j.pupt.2019.101836_bib32","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaci.2009.06.053","article-title":"The minimally important difference of the Asthma Control Test","volume":"124","author":"Schatz","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3 Suppl","key":"10.1016\/j.pupt.2019.101836_bib33","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaci.2011.12.986","article-title":"Asthma outcomes: pulmonary physiology","volume":"129","author":"Tepper","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.pupt.2019.101836_bib34","doi-asserted-by":"crossref","DOI":"10.1111\/all.13937","article-title":"Efficacy of Mepolizumab in patients with previous Omalizumab treatment failure: real life observation","author":"Bagnasco","year":"2019","journal-title":"Allergy"},{"issue":"8","key":"10.1016\/j.pupt.2019.101836_bib35","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1080\/14740338.2016.1186641","article-title":"The safety of monoclonal antibodies in asthma","volume":"15","author":"Passalacqua","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"issue":"5","key":"10.1016\/j.pupt.2019.101836_bib36","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.pupt.2019.101836_bib37","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1183\/20734735.015414","article-title":"Real-world research and its importance in respiratory medicine","volume":"11","author":"Price","year":"2015","journal-title":"Breathe"},{"issue":"2","key":"10.1016\/j.pupt.2019.101836_bib38","first-page":"119","article-title":"Biomarkers in obstructive respiratory diseases: an update","volume":"54","author":"Braido","year":"2012","journal-title":"Panminerva Med."},{"key":"10.1016\/j.pupt.2019.101836_bib39","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.pupt.2017.05.007","article-title":"IL-13 and idiopathic pulmonary fibrosis: possible links and new therapeutic strategies","volume":"45","author":"Passalacqua","year":"2017","journal-title":"Pulm. Pharmacol. Ther."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553919301270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553919301270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:29:58Z","timestamp":1761082198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553919301270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":39,"alternative-id":["S1094553919301270"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2019.101836","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"One year of mepolizumab. Efficacy and safety in real-life in Italy","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2019.101836","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101836"}}